Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

Area of Science:

• Immunology
• Neuroimmunology
• Pharmacology

Background:

• Interferon beta (IFNbeta) is a common treatment for multiple sclerosis (MS).
• Development of neutralising antibodies (NAbs) against IFNbeta can impair treatment efficacy.
• Factors like dose, frequency, and formulation influence NAb development.

Purpose of the Study:

• To review the clinical relevance of NAbs in MS patients treated with IFNbeta.
• To discuss factors affecting IFNbeta immunogenicity and NAb formation.
• To address the need for standardized NAb assays and clinically relevant titre definitions.

Main Methods:

• Expert panel review and synthesis of existing literature.
• Discussion of immunogenicity factors and assay methodologies.
• Analysis of clinical data linking NAb status to treatment response.

Main Results:

• Strong evidence indicates NAb status negatively impacts clinical efficacy in MS patients.
• Lack of standardized assays and variable titres over time complicate NAb assessment.
• NAb testing is crucial for managing IFNbeta therapy responsiveness.

Conclusions:

• Standardized NAb testing is essential for optimal MS patient care.
• Defining clinically relevant NAb titres will improve treatment monitoring.
• Further research is needed to fully understand and manage IFNbeta immunogenicity.